Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma

International Journal of Hematology

Volumn 77, Issue 5, 2003, Pages 512-517

  Tobinai, Kensei ^a   Uike, Naokuni ^b   Saburi, Yoshio ^c   Chou, Takaaki ^d   Etoh, Tetsuya ^e   Masuda, Masato ^f   Kawano, Fumio ^g   Matsuoka, Masao ^h   Taguchi, Hirokuni ⁱ   Makino, Torahiko ^j   Asano, Yoshinobu ^k   Tamura, Kazuo ^l   Ohashi, Yasuo ^m  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c OITA PREFECTURAL HOSPITAL   (Japan)

^d Niigata Cancer Center   (Japan)

^e HARASANSHIN HOSPITAL   (Japan)

^f UNIVERSITY OF THE RYUKYUS   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

^h KUMAMOTO UNIVERSITY   (Japan)

ⁱ KOCHI MEDICAL SCHOOL   (Japan)

^j IMAMURA BUN IN HOSPITAL   (Japan)

^k KYUSHU UNIVERSITY   (Japan)

^l FUKUOKA UNIVERSITY   (Japan)

^m UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

2 CdA; 2 Chlorodeoxyadenosine; Adult T cell leukemia lymphoma; ATL; Cladribine; Phase II study

Indexed keywords

CLADRIBINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; JK 6251; PIRARUBICIN; PREDNISOLONE;

ADULT; AGED; ANEMIA; ARTICLE; BACTEREMIA; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DERMATITIS; DRUG EFFICACY; FEMALE; FUNGEMIA; HEMORRHAGIC CYSTITIS; HUMAN; HYPERBILIRUBINEMIA; HYPOPROTEINEMIA; INFECTION; LUNG HEMORRHAGE; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUTROPENIA; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROTEINURIA; T CELL LEUKEMIA; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT FAILURE; UREA NITROGEN BLOOD LEVEL;

EID: 0037670799     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02986621     Document Type: Article

References (41)

1. Uchiyama T, Yodoi J, Sagawa K, et al. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50:481-492.
2. Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T cell leukemia and its implication in the disease. Proc Natl Acad Sci U S A. 1982;79:2031-2035.
3. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79:428-437.
4. Tobinai K. Adult T-cell leukemia-lymphoma. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, eds. Clinical Oncology. 2nd ed. New York, NY: Churchill Livingstone; 2000:2748-2768.
5. Shimoyama M, Ota K, Kikuchi M, et al. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M. J Clin Oncol. 1988;6:128-141.
6. Shimoyama M, Ota K, Kikuchi M, et al. Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia. J Clin Oncol. 1988;6:1088-1097.
7. Tobinai K, Shimoyama M, Minato K, et al. Japan Clinical Oncology Group phase II trial of second-generation "LSG4 protocol" in aggressive T- and B-lymphoma: a new predictive model for T- and B-lymphoma [abstract]. Proc Am Soc Clin Oncol. 1994;13:378.
8. Tobinai K, Shimoyama M, Inoue S, et al. Phase I study of YK-176 (2′-deoxycoformycin) in patients with adult T-cell leukemia-lymphoma. Jpn J Clin Oncol. 1992;22:164-171.
9. Shimoyama M. Chemotherapy of ATL. In: Takatsuki K, ed. Adult T-cell Leukaemia. Oxford, UK: Oxford University Press; 1994:221.
10. Tsukasaki K, Tobinai K, Shimoyama M, et al. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol. 2003;77:164-170.
11. Carson DA, Kaye J, Seegmiller JE. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). Proc Natl Acad Sci U S A. 1977;77:5677-5681.
12. Carson DA, Wasson DB, Kaye J, et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci U S A. 1980;77:6865-6869.
13. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet. 1992;340:952-956.
14. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990;322:1117-1121.
15. Tallman MS, Hakimian D, Variakojis D, et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood. 1992;80:2203-2209.
16. Juliusson G, Liliemark J. High complete remission rate of 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol. 1993;11:679-689.
17. Saven A, Lemon RH, Kosty M, Beutler E, Piro LD. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol. 1995;13:570-574.
18. Barton K, Larson RA, O'Brien S, Ratain MJ. Rapid response of B-cell prolymphocytic leukemia to 2-chlorodeoxyadenosine [letter]. J Clin Oncol. 1992;10:1821.
19. Kay AC, Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol. 1992;10:371-377.
20. Hoffman M, Tallman MS, Hakimian D, et al. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced non-Hodgkin's lymphoma. J Clin Oncol. 1994;12:788-792.
21. Saven A, Emanuele S, Kosty M, Koziol J, Ellison D, Piro L. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood. 1995;86:1710-1716.
22. Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest. 1985;75:377-383.
23. Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood. 1992;80:587-592.
24. O'Brien S, Kurzrock R, Duvic M, et al. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood. 1994;84:733-738.
25. Kuzel TM, Hurria A, Samuelson E, et al. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood. 1996;87:906-911.
26. Tobinai K, Ogura M, Hotta T, et al. Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Jpn J Clin Oncol. 1997;27:146-153.
27. Uike N, Choi I, Tokoro A, et al. Adult T-cell leukemia-lymphoma successfully treated with 2-chlorodeoxyadenosine. Intern Med. 1998;37:411-413.
28. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10.
29. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
30. Tobinai K, Kohno A, Shimada Y, et al. Toxicity grading criteria of the Japan Clinical Oncology Group (JCOG). Jpn J Clin Oncol. 1993;23:250-257.
31. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization; 1979. Publication No. 48.
32. Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001;113:375-382.
33. Taguchi H, Kinoshita K, Takatsuki K, et al. An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12:182-186.
34. Sparano JA, Wiernik PH, Strack M, et al. Infusional cyclophosphamide, doxorubicin, and etoposide in human immunodeficiency virus- and human T-cell leukemia virus type 1-related non-Hodgkin's lymphoma: a highly active regimen. Blood. 1993;81:2810-2815.
35. Waldmann TA, White JD, Goldman CK, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotropic virus I-induced adult T-cell leukemia. Blood. 1993;82:1701-1712.
36. Waldmann TA, White JD, Carrasquillo JA, et al. Radioimmunotherapy of interleukin-2Rα-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood. 1995;86:4063-4075.
37. Zhang M, Yao Z, Garmestani K, et al. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the α-emitting radionuclide, bismuth 213. Blood. 2002;100:208-216.
38. Ishitsuka K, Hanada S, Suzuki S, et al. Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids. Br J Haematol. 1998;103:721-728.
39. Bazarbachi A, El-Sabban ME, Nasr R, et al. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood. 1999;93:278-283.
40. Utsunomiya A, Miyazaki Y, Takatsuka Y, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27:15-20.
41. Abe Y, Yashiki S, Choi I, et al. Eradication of virus-infected T-cells in a case of adult T-cell leukemia/lymphoma by nonmyeloablative peripheral blood stem cell transplantation with conditioning consisting of low-dose total body irradiation and pentostatin. Int J Hematol. 2002;76:91-93.